Cogent Biosciences
Yahoo Finance • 11 months ago
15 Small-Cap Stocks with High Potential
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stock... Full story
Yahoo Finance • last year
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two poster... Full story
Yahoo Finance • last year
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSM data selected for oral presentation SUMMIT Part I completed upsized enrollment during Q3; SUMMIT Part 2 expected to begin in 1H 2024 at over 50... Full story
Yahoo Finance • last year
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – - IND and initiation of clinical trial planned in 2H 2024 -... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
WALTHAM, Mass. and BOULDER, Colo., June 09, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results
Lead-in data from Phase 3 PEAK trial to be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting Announced initiation of APEX Part 2 expansion trial; on-track to present initial SUMMIT clinical data in 2H 2023... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations In vivo characterization shows a novel, selective, reversible FGFR2 inhibitor has potency against molecular brak... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
Initiation of APEX Part 2 planned for mid-2023 Updated clinical data from Phase 3 PEAK lead-in in GIST patients expected 1H23 Initial clinical data from Phase 2 SUMMIT trial in NonAdvSM on-track for 2H23 Ended 2022 with $259.3 million in c... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
WALTHAM, Mass. and BOULDER, Colo., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from Phase 2 APEX trial in AdvSM patients and initial clinical data in 2H23 from Phase 2 SUMMIT trial in NonAdvSM patients... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
- 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up - Rapid and deep responses seen including first confirmed CR at 20 weeks; 77% of patients with at least 2 cycles of treatment had... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development
WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appoint... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in phase to be presented at CTOS 2022 Ph... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced upcoming pr... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it wil... Full story
Yahoo Finance • 2 years ago
2 Monster Growth Stocks That Could Reach New Highs
Every investor knows that you can’t look to a stock’s past performance as predictor of future gains. It’s become axiom, even, one of the stock phrases that we all learn about in Econ 101: ‘Past performance does not guarantee future returns... Full story
Yahoo Finance • 2 years ago
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
On-track to present additional data from Phase 2 APEX trial by the end of 2022 Initial data from Phase 2 SUMMIT trial & lead-in data from Phase 3 PEAK trial planned for 1H23 Ended 2Q 2022 with $325.6 million, including $172.6 million in... Full story
Yahoo Finance • 3 years ago
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closi... Full story
